Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Eman L. Dadashian"'
Autor:
Sarah E. M. Herman, Adrian Wiestner, Ari Melnick, Hana Safah, Chingiz Underbayev, Cydney M. Nichols, Erik K. Flemington, Lorena Fontan, Delong Liu, Eman L. Dadashian, Patricia Lobelle-Rich, Jessica R. Iyer, Georges Tanios, Deanna H. Wong, Nakhle S. Saba
Description and Legends for Supplementary Tables S1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7ca9fc31b0aadb73d9e2bfcc71cf44
https://doi.org/10.1158/0008-5472.22416350.v1
https://doi.org/10.1158/0008-5472.22416350.v1
Autor:
Sarah E. M. Herman, Adrian Wiestner, Ari Melnick, Hana Safah, Chingiz Underbayev, Cydney M. Nichols, Erik K. Flemington, Lorena Fontan, Delong Liu, Eman L. Dadashian, Patricia Lobelle-Rich, Jessica R. Iyer, Georges Tanios, Deanna H. Wong, Nakhle S. Saba
The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell receptor signaling, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10bf90727eb627a2e58fb54bc0fdd596
https://doi.org/10.1158/0008-5472.c.6509528
https://doi.org/10.1158/0008-5472.c.6509528
Autor:
Sarah E.M. Herman, Adrian Wiestner, Brian J. Lannutti, Roger Ulrich, Raquel Izumi, Nicholas Chiorazzi, Shih-Shih Chen, Todd Covey, Fanny Krantz, Eman L. Dadashian, Helena I. Mora-Jensen, Carsten U. Niemann
Supplementary methods and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9e963db2def1ccd6770542861e7c6d
https://doi.org/10.1158/1078-0432.22466763
https://doi.org/10.1158/1078-0432.22466763
Autor:
Sarah E. M. Herman, Adrian Wiestner, Louis M. Staudt, Michael J. Kruhlak, Jessica R. Iyer, Ryan M. Young, Arthur L. Shaffer, Delong Liu, Erin M. McAuley, Eman L. Dadashian
Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells driven by B-cell receptor (BCR) signaling and activated primarily in the lymph node. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib effectively inhibits BCR-dependent prolif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f2bd0ebe4046bd3c06c613313c07d9
https://doi.org/10.1158/0008-5472.c.6510918.v1
https://doi.org/10.1158/0008-5472.c.6510918.v1
Autor:
Sarah E. M. Herman, Adrian Wiestner, Ari Melnick, Hana Safah, Chingiz Underbayev, Cydney M. Nichols, Erik K. Flemington, Lorena Fontan, Delong Liu, Eman L. Dadashian, Patricia Lobelle-Rich, Jessica R. Iyer, Georges Tanios, Deanna H. Wong, Nakhle S. Saba
Supp. Fig. S1: MI-2 causes a dose- and time-dependent apoptotic induction selectively in primary CLL cells with minimal toxicity to normal B cells. Supp. Fig. S2: Sensitivity to MI-2 is independent of clinical or biological features classically assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79994f4b9b0e9d1601e4b96e7f8ed3cf
https://doi.org/10.1158/0008-5472.22416353
https://doi.org/10.1158/0008-5472.22416353
Autor:
Sarah E. M. Herman, Adrian Wiestner, Louis M. Staudt, Michael J. Kruhlak, Jessica R. Iyer, Ryan M. Young, Arthur L. Shaffer, Delong Liu, Erin M. McAuley, Eman L. Dadashian
Supplementary Figure S1: Dose response experiments with the IRAK1/4 inhibitor (IRAKi) in CLL cells. Supplementary Figure S2: TLR signaling is active in lymph node-resident CLL cells. Supplementary Figure S3: Flow Cytometry gating strategy. Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8497aed393eed621ee80443a6f84ec1c
https://doi.org/10.1158/0008-5472.22421409.v1
https://doi.org/10.1158/0008-5472.22421409.v1
Autor:
Sarah E.M. Herman, Adrian Wiestner, Brian J. Lannutti, Roger Ulrich, Raquel Izumi, Nicholas Chiorazzi, Shih-Shih Chen, Todd Covey, Fanny Krantz, Eman L. Dadashian, Helena I. Mora-Jensen, Carsten U. Niemann
Supplementary Figures 1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d35da5b1fd2d246302b9fc076dfa015
https://doi.org/10.1158/1078-0432.22466766
https://doi.org/10.1158/1078-0432.22466766
Autor:
Sarah E. M. Herman, Adrian Wiestner, Ari Melnick, Hana Safah, Chingiz Underbayev, Cydney M. Nichols, Erik K. Flemington, Lorena Fontan, Delong Liu, Eman L. Dadashian, Patricia Lobelle-Rich, Jessica R. Iyer, Georges Tanios, Deanna H. Wong, Nakhle S. Saba
Supplementary Figure Legends S1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad3627d3fe1fa7559baeb4b07114421
https://doi.org/10.1158/0008-5472.22416359.v1
https://doi.org/10.1158/0008-5472.22416359.v1
Autor:
Sarah E.M. Herman, Adrian Wiestner, Brian J. Lannutti, Roger Ulrich, Raquel Izumi, Nicholas Chiorazzi, Shih-Shih Chen, Todd Covey, Fanny Krantz, Eman L. Dadashian, Helena I. Mora-Jensen, Carsten U. Niemann
Purpose: Targeting the B-cell receptor (BCR) pathway with inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ is highly effective for the treatment of chronic lymphocytic leukemia (CLL). However, deep remissions are uncommon, and drug resistance wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a0fddd823adb7de6d26575573dd0c29
https://doi.org/10.1158/1078-0432.c.6526416.v1
https://doi.org/10.1158/1078-0432.c.6526416.v1
Autor:
Sarah E. M. Herman, Adrian Wiestner, Ari Melnick, Hana Safah, Chingiz Underbayev, Cydney M. Nichols, Erik K. Flemington, Lorena Fontan, Delong Liu, Eman L. Dadashian, Patricia Lobelle-Rich, Jessica R. Iyer, Georges Tanios, Deanna H. Wong, Nakhle S. Saba
Supplementary Table S1. Patient characteristics. Supplementary Table S2. Characteristics of patients treated with ibrutinib. Supplementary Table S3. Primers and probes used for digital PCR. Supplementary Table S4. List of genes up- or down-regulated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa82218c44ae52bb5bf32f818401035
https://doi.org/10.1158/0008-5472.22416347
https://doi.org/10.1158/0008-5472.22416347